Drug Profile
TKM 130803
Alternative Names: siEbola-3 - Arbutus Biopharma; TKM-130803; TKM-Ebola-GuineaLatest Information Update: 29 Oct 2016
Price :
$50
*
At a glance
- Originator Tekmira Pharmaceuticals Corporation
- Developer Arbutus Biopharma; University of Oxford
- Class Antineoplastics; Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Suspended Ebola virus infections
Most Recent Events
- 25 Oct 2016 Suspended - Phase-II for Ebola virus infections in Sierra Leone (IV, Infusion) (Arbutus Biopharma pipeline; October 2016)
- 25 Oct 2016 Efficacy and safety data from the phase II RAPID-TKM trial in Ebola virus infections released by Arbutus Biopharma
- 19 Apr 2016 Arbutus Biopharma terminates the phase II RAPID-TKM trial in Ebola virus infections in Sierra Leone due to futility rule (IV, Infusion)